ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced treatment with ANKTIVA® (nogapendekin alfa ...

Patients on tirzepatide also experienced more metabolic benefits, such as greater reductions in weight and HbA1c, compared ...

Combination therapy with nogapendekin alfa inbakicept and BCG achieved a 3-year DSS rate of 96% in BCG-unresponsive NMIBC ...

Among persons at high cardiovascular risk, there is low- to moderate-certainty evidence that reducing or modifying saturated ...

Cancer patients and survivors are more likely to report housing and utility insecurity than those who do not have a history of cancer, according research ...

A meta-analysis showed that reducing saturated fat intake was associated with reduced mortality, albeit only in high-risk ...

The analysis found higher odds of myocardial infarction among e-cigarette users, particularly former smokers, while no ...

Low-volatility ETFs are in focus as JPMorgan warns of overcrowding in speculative AI and growth stocks, prompting a rethink ...

Adrian Kempe scored twice in the second period, and the Los Angeles Kings beat the Tampa Bay Lightning 2-1. Anton forsberg ...

In patients with diabetes and multivessel coronary artery disease undergoing percutaneous coronary intervention, ticagrelor ...

Background Early cardiovascular disease risk detection opportunities are limited in men, whereas gestational diabetes, ...

The results of the Precision-T Phase 3 study of investigational allogeneic T-cell immunotherapy, Orca-T, were published in the journal Blood.